Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.2761 | 0.3067 | 0.0685 |
Onchocerca volvulus | 0.4583 | 1 | 0.5 | |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.2761 | 0.3067 | 0.3067 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.4506 | 0.9706 | 0.9706 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.2761 | 0.3067 | 0.3067 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4506 | 0.9706 | 0.9706 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.2705 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.2705 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.4583 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.2705 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.2705 | 0.2852 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.4506 | 0.9706 | 0.9706 |
Schistosoma mansoni | 6-phosphofructokinase | 0.4583 | 1 | 1 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.2761 | 0.3067 | 0.3067 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.4506 | 0.9706 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.4583 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.2705 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.4506 | 0.9706 | 0.9604 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.2761 | 0.3067 | 0.0778 |
Brugia malayi | kinase, mitochondrial precursor | 0.2761 | 0.3067 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.